بدائل البحث:
significant decrease » significant increase (توسيع البحث), significantly increased (توسيع البحث)
significantly i » significantly _ (توسيع البحث), significantly high (توسيع البحث), significantly less (توسيع البحث)
significant decrease » significant increase (توسيع البحث), significantly increased (توسيع البحث)
significantly i » significantly _ (توسيع البحث), significantly high (توسيع البحث), significantly less (توسيع البحث)
-
421
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
منشور في 2025"…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
-
422
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
منشور في 2025"…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
-
423
-
424
Summary of post-treatment disease course measures from MDMA-AT publications.
منشور في 2025الموضوعات: -
425
-
426
Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.
منشور في 2025الموضوعات: -
427
-
428
-
429
-
430
Summary of post-treatment disease course measures from off-label medications clinical trials.
منشور في 2025الموضوعات: -
431
Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.
منشور في 2025الموضوعات: -
432
Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.
منشور في 2025الموضوعات: -
433
Summary of post-treatment disease course measures from clinical trials with psychotherapies.
منشور في 2025الموضوعات: -
434
-
435
-
436
Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.
منشور في 2025الموضوعات: -
437
-
438
-
439
Altered expression of genes related to Ca<sup>2+</sup> cycling or myocardial contraction.
منشور في 2025الموضوعات: -
440